source r&d directory

Source R&D 1

Company Profiles

R&DFinding your CRO/CMO partner

2015 Source R&D Directory - a new initiative from

Source R&D2

Company Profiles

IFCgenesis 2015

London’s premierLife Science & Healthcarenetworking conference

10 December 2015

Queen Elizabeth II Conference Centre Westminster, London, UK

genesisconference.com

Source R&D 3

Company Profiles

Listings for One Nucleus and

Bionow CRO, CMO and service

provider member companies

Contents

Company Profiles

R&D Outsourcing

Contact Information

4

7

15

Tony Jones of One Nucleus,

Geoff Lawton of INMedD and

Chris Keep of AstraZeneca on the

R&D outsourcing business environment

Abzena plc 7

AMS Biotechnology (Europe) Limited 8

Cambridge Research Biochemicals 8

Catalent Pharma Solutions 9

Evotec 10

Isogenica 12

New England Biolabs (UK) Ltd 13

Pathology Diagnostics Ltd 14

ProSynth Limited 14

Cover image from iStock.com © scanrail

The Source R&D Directory is published on behalf of One Nucleus and Bionow by Hartswood Media, Hallmark House, 25 Downham Road, Ramsden Heath CM11 1PU, United KingdomTel: +44 (0)1277 211691 Email: [email protected]

Printed by Manor Creative Ltd, Eastbourne, East Sussex, United Kingdom.

Source R&D4

Company Profiles

The origins of the work One Nucleus has undertaken over the past year with regard to supporting the service provision cohort of our sector stem from a number of observations about our membership diversity and the

changing industry landscape. There is also an apparent under-estimation of the expertise, translational research competence and economic value of the service sector in various quarters. The increasing externalisation and partnership approach to new medicine discovery means that any region may need to position itself as an outsourcing location of choice – not due to cost but due to provision of a highly connected drug discovery and development supply chain.

We have explored the changing role and challenges of the R&D service providers in the Life Sciences landscape. It is clear that many of the challenges are common across all service-based industries and are sector agnostic, such as the ‘them and us’

culture among clients and a feeling of supplying commoditised services and goods. The sector is believed to be worth an estimated $10 billion, with up to 500 CRO and CMO organisations in the UK, but there is a dearth of accurate and validated data to confirm this. A contributing factor in this is defining the R&D services sector given the diverse set of roles it encompasses along the drug discovery and development pipeline. Defining this sector, for example by company numbers, annual turnover or number of employees, is an important goal to attract more business and enable effective advocacy by the appropriate associations.

Increasing demand appears to be fuelled from the discovery, rather than development, stage of the R&D pipeline. This could be expected in light of the down-sizing of the pharmaceutical industry’s internal early-stage efforts, and the consequential need to invest in discovery via external contracts. Another factor is the increasing focus of venture funds on asset-centric

The business environment in which new medicines are invented has been completely transformed in the past two decades.

Biopharma 1.0 had thrived for fifty years providing many new medicines and also good returns to investors. The vast majority of the work was carried out in fully integrated pharmaceutical companies (FIPCOs). These businesses owned the portfolio of projects and also owned the laboratory facilities where the operations were carried out by talented scientists employed by the FIPCO. Productivity in FIPCOs is now widely perceived to provide very poor return on research investment. Tomes have been written on the reasons for this decline, which are many and varied.

The large pharma companies have severely reduced their internal research investment and now increasingly look to a range of external providers to deliver their drug candidates. Biopharma 2.0 has evolved in response and is now becoming established. This is a much more diverse landscape where partnerships between different businesses are the norm. The many skills required for creating a new medicine can now be provided by separate specialist companies. Clinical research expertise was the first to be made available via contract arrangements. Today all of the many required drug discovery skills can be accessed through specialist providers.

Contract research organisations (CRO) are increasingly replacing FIPCOs as the largest repository of expertise in all aspects of drug discovery and development. For example, some large

pharma companies use CROs to provide almost all of their clinical development operations. The extent of the change with respect to chemistry was discussed by Chris Newton, Senior Vice President at Galapagos NV, in a recent presentation (RSC/SCI September 2014). In the UK, his survey revealed that the number of drug discovery chemists employed by CROs is now more than 50% of the total.

Use of CROs allows separation of the ownership (and funding) of the project portfolio from the organisations operating the projects. The financial portfolio does not have to be the same as the operational portfolio. At one extreme, as was usual in Biopharma 1.0, the operator of a project portfolio would also be the funder/investor. At the other extreme, the projects within the funded portfolio can each be managed virtually and operated by one or more CROs. Flexible control of financial commitments and more effective risk management are key advantages for investors in Biopharma 2.0.

CROs are critical to the future of medicine discovery. No aspect of the process is static and continuous development is essential. Training, personal development and nurturing the skills was previously undertaken by FIPCOs. Who will be responsible in BioPharma 2.0?

For specialist technologies this is already largely in CROs. Many CROs are attractive to their clients because of their technical expertise. The ability to focus on a single skill and provision to multiple clients allows them to develop critical mass and to become world leaders in their skill set. The more generic skills of project and

One Nucleus and the Source R&D Directory

The role of CROs in the De-aggregated Biopharma system

R&D Outsourcing

Source R&D 5

Company Profiles

investments and virtual biotech business models. There are challenges however, especially for the smaller companies supplying these R&D services. Sponsors are running much slimmer portfolios, resulting in fewer but larger projects that tend to be attractive to larger one-stop-shop style providers. In their competitive environment, there is significant pressure to reduce margins yet balance winning contracts with sustainability. Furthermore, the procurement process and the key performance indicators attached to the role of purchasing officers within clients often squeeze the provider on price. A strategy ill-aligned with sustainability of the supplier. This can be exacerbated for SMEs when Government-supported new entrants with reduced or subsidised overheads can under-price projects whilst the larger providers have sufficiently strong balance sheets to offer lost-leader bids.

Image has been a key element that has led One Nucleus to produce the Source R&D Directory. The contract sector suffers from something of an image and identity crisis - perhaps as a result of being under-valued by sponsors and policymakers as commodity rather than high-value-adding expertise. There are innumerable positioning terms used within the fee-for-service cohort, partly to address the above prejudices, but to also accurately reflect their often proprietary offer. The terminology

can include straight CRO and CMO, solution providers, R&D collaborators and many more, each with their own perfectly justified rationales for differentiation. A positive self-image is required that encompasses this diversity and collective excellence. One Nucleus has taken the initiative in correcting this image by showcasing the expertise and value-adding offer from the service sector. The Source R&D Directory is a vital part of the strategy, enabling clients, partners and policy makers to fully navigate and understand the manifold benefits of the R&D Services sector. We are delighted Bionow have joined us in supporting our respective providers in this inaugural publication of the Source R&D Directory with Hartswood Media.

portfolio management have so far mostly been retained by the funder. In the short term, management of virtual programmes has been directed by individuals who gained their expertise through years of exposure to drug discovery within FIPCOs and owing to the down-sizing became available as consultants. These individuals have the tacit technical and process skills which are essential for making the critical decisions: which project, which technology, which outsource provider, which lead, which candidate, when to stop; and can provide effective management of the outsourced provisions.

Today there are many such individuals who learnt the skills in the FIPCOs where they were exposed to all of the very wide-ranging components of successful drug hunting.

BUT: where is the training ground for the next generation of drug hunters? Exposure to many successful and unsuccessful projects is a key component of the learning. Those CROs providing ‘integrated’ drug discovery ‘services’ have a great opportunity to effectively develop the high level skills and to be knowledge leaders. Impediments including a heavy focus on cost-containment and the need for firewalls between projects will need to be overcome.

CROs are a key component of the future system. Many business models are available.

A pure fee-for-service company generates experimental data and the rights to this IP are wholly owned by the client. The range of providers includes those that carry out experiments to the client’s design through to those that provide all of the design, the client simply providing the funding and cost control. All of the many facets of drug discovery from target discovery through candidate identification and clinical development can be sourced from this type of business structure. Some providers can offer a ‘one-stop shop’, while others provide only single skill sets and the client puts together a supply chain of providers. A growing number of CROs fall into a

hybrid category where they are prepared to assume a share of the risk in return for appropriate reward for success.

As the BioPharma system continues to dis-aggregate, a range of different investor types can be accommodated within one operational portfolio and conversely, a single funder can carry out its projects in different operational business structures. There is now increasing recognition that partnerships between different stakeholders are essential in the new landscape of Biopharma 2.0. At present the partnerships are usually formed and controlled by large pharma companies (FIPNET). Almost all big pharma companies now advertise themselves as the hub of a network of partnerships and collaborations. It is likely that the drivers of future partnerships will include a wider spectrum of stakeholders. These will include venture philanthropists, medical insurance companies and governments. We are already seeing the emergence of, for example, The Wellcome Trust, Bill & Melinda Gates Foundation, Michael J Fox and Cystic Fibrosis Foundation using their power to bring together the components of the supply chain. CROs are a critical component of this evolving system.

R&D Outsourcing

Tony Jones – Business Development Director at One Nucleus

Geoff Lawton – consultant, founder of INMedD

Source R&D6

Company Profiles

Increasingly we are working in a world of multiple delivery models and many external suppliers, collaborators and partners.

Being a supplier, a partner and a collaborator is not easy and requires significant effort in many areas beyond simply delivering the

contracted scientific/clinical outputs; these include reducing delivery lead times; increasing cost efficiency and actively managing the business relationships with pharma sponsors.

A variety of delivery models and approaches are used with pharma organisations, with companies often moving between models over time. We are not seeing one approach as being significantly better than another; instead we see that tailoring the solution to the client’s requirement is becoming more important. Regardless of the approach adopted, the key is commitment and support to execute well, dealing with issues that inevitably come up rather than losing faith in earlier decisions.

In addition to the classical CRO (Contract or, to some, Clinical Research Organisation), there also exists the ARO (Academic Research Organisation). The latter, often associated with universities, hospitals, charities and other not-for-profit institutions, are also playing an increasing role in clinical development and occasionally competing with the CROs. In our experience the many differences between these two distinct types of partner requires a more tailored approach.

Contract Research OrganisationsThe CRO industry is maturing with continued consolidation resulting in global suppliers emerging. These suppliers are creating tailored and full-service delivery solutions for their pharma sponsors and as such several sponsors have subsequently formed closer relationships/partnerships with preferred supplier CROs. Pharma will continue to maintain preferred relationships with a small number CRO partners who share a vision for ‘performance based partnership’, with these relationships only realising their full potential where objectives are aligned, where there is continued investment on both sides and ultimately mutual benefit.The essential characteristics of successful CRO/pharma partnerships are:• High levels of trust, with clear accountability for quality, delivery and cost and increased openness and commercial transparency • Customer preference, with CROs adopting a differentiated approach to their most important customers, for example providing their most experienced and capable resources or granting early access to innovation• Sustained performance over time, driven by continuous improvement, simplification and technology enablement• Shared culture of collaboration, focusing on the partner’s needs and acting upon feedback

For the CROs, the benefits are multiple and can include:• Increased share of the sponsor’s business• Improved revenues and margins through shared efficiency gains • Longer-term agreements • Deeper relationships with their sponsors

Academic Research Organisations (AROs) and Collaborative Groups (CGs)The driver for these groups is scientific leadership. For the sponsor, AROs and CGs offer unique capabilities.

Working in this type of relationship often requires greater adaptability from both parties in order to work successfully together, particularly in the business contractual relationship. Some reasons for this include:• AROs and CGs don’t always see the similarities that they have with CROs even though some aspects of the delivery models are common• Their geographic footprint is predominantly regional and rarely global• In some cases their business models and practices are less mature than those of pharma companies and CROs, with fewer experienced business people allocated to developing scope, budgets, terms & conditions and compliance processes • They may find it more difficult to provide the increasing transparency reporting expected of pharma companies in dealing with HCPs and Healthcare Institutions (eg US Open Payments, Fair Market Value, ABAC)• Greater overhead charges on top of professional fee costs vary.

Owing to some of the gaps in capability sometimes a hybrid ARO-CRO delivery model is required, particularly for large-scale clinical trials.

Clearly one size does not fit all with AROs and CGs, and consequently the sponsor needs to consider the relative balance between scientific leadership, delivery risk and cost when considering a relationship with an ARO or CG. Employing some simple ‘rules’ can often help:• Operationally:• Try to minimise the size of the pharma company’s internal team that interacts with the ARO or CG on a day-to-day basis with clearly defined core team roles and single points of contact• Use common tools or processes with emphasis on efficiency and cost effectiveness• Set clear expectations on the use of established preferred suppliers for core enabling services while considering the benefit of using an ARO or GC’s partner• Culturally:• Enter the relationship with the right mindset – adopting a ‘ learner’ frame of reference versus that of a ‘knower’ ensures curious, constructive conversations and helps to build trust, resulting in the development of new ways to work together more effectively• Demonstrate ‘integrative thinking’, understand the interdependencies and dealing with complex aspects while keeping sight of the bigger picture • Find solutions that don’t force choices between options which appear to be mutually exclusive

The ‘Delivery Marketplace’ we are working in - Pharma, CROs and AROs working together…

Chris Keep of AstraZeneca

R&D Outsourcing

Chris Keep is Global Category Leader, Academic & Healthcare Professionals Services, GMD Procurement at AstraZeneca based in Macclesfield, United Kingdom. Tel: +44 (0)1625 513718 Email: [email protected]

Source R&D 7

Company Profiles

Abzena provides a suite of complementary services and technologies to R&D organisations to select and create better therapeutic proteins and antibodies with less risk of failure in clinical development and it is therefore poised to capitalise on

the growth of the biopharmaceutical market. The Group’s technologies and services are provided through its wholly owned subsidiaries, PolyTherics and Antitope.

PolyTherics and Antitope have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.

Antitope’s services and technologies enable the selection and creation of antibodies and proteins with reduced potential to be immunogenic in patients. Antitope can also develop manufacturing cell lines for these and other therapeutic antibodies and proteins.

PolyTherics offers product-specific licences for the application of its conjugation and polymer technologies to enable the development of more stable and homogeneous antibody drug conjugates (ADCs) and product candidates with extended in vivo half-life.

Services and technologiesImmunogenicity assessmentEpiScreen™ is an accurate and sensitive way to assess the potential immunogenicity of proteins and antibodies ex vivo by measuring CD4+ T cell responses, the primary drivers of memory-based immunogenicity. This method has been used across the industry to assess risk at the preclinical stage. Antitope also provides rapid high-throughput in silico analysis of MHC class II binding and T cell epitope location with iTOPE™ and TCED™.Antibody humanisation and protein deimmunisationComposite Human Antibody™ and Composite Protein™ services are used to create biopharmaceuticals devoid of the T cell epitopes that lead to an

adverse immune response while minimising the loss of antibody affinity or protein activity that can occur with standard protein engineering techniques.

Cell line development High-expressing mammalian cell lines are developed for the production of specific partner antibodies and proteins, including biosimilars, using Composite CHO™, NS0, Sp2/0 or other cell lines. Cell lines suitable for commercial manufacture can be transferred to your own manufacturing facility or directly to your preferred GMP contract manufacturingorganisation.

Antibody drug conjugates PolyTherics has developed its range of novel ThioBridge™ linkers to efficiently conjugate drugs to antibodies to create less heterogeneous ADCs with better stability. Its proprietary technology uses site-specific conjugation to naturally occurring inter-chain disulfides avoiding the need for antibody re-engineering.

Optimisation of pharmacokineticsPolyTherics’ proprietary PEGylation technologies enable polyethylene glycol (PEG) or other polymers to be conjugated to specific sites to extend the in vivo half-life of therapeutic proteins. TheraPEG™ conjugates PEG at disulfide bonds, HiPEG™ to poly-histidine motifs and CyPEG™ to a thiol on a free cysteine. PolyTherics’ has conjugated both linear and branched PEG and its proprietary low-viscosity polymer, PolyPEG™ to a variety of therapeutic proteins.

Contact Information: Abzena plcTel: +44 (0) 1223 903498Email: [email protected]: www.abzena.com

Source R&D8

Company Profiles

Founded in 1987, AMS Biotechnology (AMSBIO) is recognised today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology,

products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production,CRISPR/Cas9 Genome Editing,lentivirus and adenovirus production, large-scale protein production and a comprehensive portfolio of antibody services.

Contact Information:AMS Biotechnology (Europe) LimitedTel: +44 (0)1235 828200Email: [email protected]: www.amsbio.co.uk

Cambridge Research Biochemicals (CRB) offers over 34 years of expertise as a provider of custom peptides and bespoke antibody tools, to Pharmaceutical, Biotechnology and Research Institutes throughout the world. The superior

quality of the products and services combined with the complexity and intricacy of the majority of projects undertaken is showcased via customer testimonials and publications.

CRB offers the highest quality custom made polyclonal and monoclonal antibodies, in addition to custom synthesis of peptides of various flavours including stable-isotope, radio-isotope and fluorescently labelled products at the highest level of purity, from milligram to gram scale. Detailed technical consultation on peptide and antibody design is offered and a dedicated customer service team is in place. CRB also offers the most comprehensive range of proprietary dyes for labelling peptides, proteins and antibodies and has a licence in place to perform ‘Click’ labelling of peptides and

proteins from The Scripps Research Institute.CRB is a preferred supplier to the MRC and recently relocated and

expanded the business, moving to a 10,000 sq ft facility named ‘The Gardner Ratcliffe Building’ after two highly esteemed collaborators. Equipped with brand-new state-of-the-art laboratory equipment and office space, the expansion has allowed CRB to increase production capacity and further enhance the peptide and antibody portfolio.

Contact Information:Cambridge Research BiochemicalsTel: +44 (0) 1642 567180Email: [email protected]: www.crbdiscovery.com

CRB’s expanded new premises, The Gardner Ratcliffe Building

Source R&D 9

Company Profiles

Catalyst + Talent. Catalent’s name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, Catalent is the catalyst for your success. With more than 80 years of experience across

Rx and consumer markets, the company has the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results.Catalent develops. With its broad range of expert services Catalent drives faster, more efficient development timelines to help you take more molecules to market and create more effective products.Catalent delivers. As the world leader in drug delivery innovations, Catalent has a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments.Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, Catalent provides integrated solutions to take your product from design, to clinical trial, to plant, and to pharmacy.

Catalent. More products. Better treatments. Reliably supplied.™

Catalent RP Scherer softgel technologiesCatalent is the world leader of softgel drug delivery technologies. As the originator of the RP Scherer softgel rotary die process, Catalent has 80 years of global manufacturing expertise and produces a majority of branded prescription softgel products. Catalent has the breadth and depth of expertise in gelatin/non-gelatin based softgel technologies to solve your toughest drug delivery challenges.

Modified release technologiesFrom drug development services to delivery technologies and supply solutions, Catalent is the catalyst for your success. Catalent has the deepest expertise and the most innovative drug delivery technologies to enhance your product performance, including OSDrC® OptiDose™ optimised dosing, Zydis® fast-dissolve formulations and OptiMelt™ hot melt extrusion.

BiologicsCatalent is your strategic partner for biologic drug development success. The company creates smart, tailored solutions with its novel SMARTag™ ADC Technology, its market

leading GPEx® cell line expression system, clinical biomanufacturing capabilities and integrated development, analytical and clinical supply services to help you get better products to clinic faster.

Development and analytical solutionsCatalent, the world’s No. 1 Formulation and Development partner, leads the industry with laboratory and chamber capacity, operational excellence, on-time delivery of reports and effective regulatory assessment. Its integrated services provide unique partnering efficiencies to ensure advancement of your large- or small-molecule product through development and registration to commercialisation.

Clinical supply servicesTailored solutions from a global leader. With over 25 years of clinical trial supply experience, serving more than 4,500 clinical trials, Catalent has the resources and expertise to deliver cost-effective and time-sensitive solutions around the world. Whether you are seeking standalone support or a comprehensive package, Catalent has the right solution for you. Its customer-centric project management and integrated solutions will help accelerate your project and provide peace of mind. Clinical expertise and offerings span all facets of clinical trials, including: • Clinical scale manufacturing• Direct global comparator sourcing• Clinical packaging and labelling• Warehousing, distribution, and returns management.

Contact Information:Catalent Pharma SolutionsTel (USA): +1 888 765 8846Tel (Europe): 00800 88556178Email: [email protected]: www.catalent.com

Source R&D10

Company Profiles

Evotec is a drug discovery solutions company providing drug discovery expertise and capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. Drug discovery solutions are provided in the form of fee-

for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, pain, metabolic diseases, oncology, infection and inflammation. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.

Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease.

Evotec is built on integrated drug discovery know-how of 20 years

and is a leading player in the drug discovery field. The company’s headquarters are located in Hamburg, Germany. Additional major operating sites exist in Abingdon, UK; Göttingen and Munich, Germany; and South San Francisco and Branford, USA. Evotec has more than 600 employees worldwide.

Evotec’s servicesTarget identification & validationHit identificationCompound management Medicinal chemistryADME profilingProteomics and biomarker scienceCell and protein productionIn vitro pharmacologyIn vivo pharmacologyIntegrated services

Contact information: Evotec (UK) LtdTel: +44 (0)1235 861561Email: [email protected]: www.evotec.com

Source R&D 11

Company Profiles

Delivering results with

The world has changed and pharma now needs to be not just fast, but first. Through our extensive drug development knowledge, we provide access to a wide portfolio of APIs and Intermediates, along with industry-leading technology and services from our state-of-the-art research and manufacturing facilities. CPS delivers world-class Chiral Technology, HPAPIs (including cytotoxics), Steroids and Activated mPEGs.

We also provide integrated full service solutions, including drug substance, pre-formulation and drug product to solve customers’ complicated product development challenges. Partner with us, and we’ll assign you a dedicated project management team to reduce your timelines and improve your ROI. We work smarter because we know you need to get your innovations to market faster.

To bring the Power of NowTM into your business, visit www.drreddys-cps.com

The power of nowTM

the Power of Now.TM

Source R&D12

Company Profiles

Isogenica discovers antibodies, peptides and other biologics using a suite of state-of-the-art complementary technologies: from library design, fabrication, target validation through to display, selection, screening, characterisation and optimisation

of leads. Each project is managed and operated by experts in the field of protein engineering and cell-based methodologies who have gained considerable experience in industry or academia.

Notably, Isogenica is a world leader in the fabrication of novel combinatorial libraries using Colibra™ – its proprietary codon-by-codon enzyme-based library synthesis method.

Using Colibra™, Isogenica is producing the best-in-class next generation of antibody fragment libraries (scFv, VHH and Fab) that can be utilised to rapidly select and develop hits against difficult targets. Its libraries generate products that are defined by clear performance metrics for affinity, bio-manufacturing and ultimately clinical use. These can be accessed on a fee-for-service basis or through licence. Isogenica also operates Colibra™ as a service for custom library manufacture, uniquely providing customers with next-generation sequencing QA/QC procedures to guarantee library quality.

In addition to its antibody capabilities, Isogenica also has extensive experience in protein engineering and peptide selection as a tool for small-molecule drug discovery.

Isogenica’s expertise and proprietary technologies can be accessed through partnerships and licences.

Translating UK scientific excellence into global therapeutic strategies

14 July 2015 Cambridge, UK

• A unique UK Translational Research Conference

• Keynote addresses by opinion leaders

• An interactive case study based programme

• Practical insights on funding and collaborations in translational

research projects

• A networking platform for academia and businesses Our translational research conferenceonhelix.com

The Wellcome Trust Conference Centre,

Hinxton, Cambridge

Contact Information:Isogenica LtdTel: +44 (0)1799 533680Email: [email protected]: www.isogenica.com

Source R&D 13

Company Profiles

Putting Science First . . .

New England Biolabs (NEB) is a world leader in the discovery, production, and supply of reagents for the life sciences. For 40 years, NEB has been dedicated to the advancement of science, and its commitment to meeting the needs of the scientific

community by providing exceptional product quality and technical support has never wavered.

NEB is passionate about science and is driven to advance the frontiers of knowledge. As a collaborator, rather than just a vendor, NEB is committed to understanding customers’ needs and developing products to address them. It aims to support its customers’ research as though it were its own. As such, NEB is at the forefront of providing the solutions and tools necessary to accelerate scientific research and drive new discoveries.

NEB’s state-of-the-art headquarters, located in Ipswich, MA, USA, is ISO 9001, ISO 13485, ISO 14001, and LEED certified. The NEB facilities include a modern fermentation centre and laboratories for production, quality control, product development, and basic research. With a depth of experience in recombinant technologies, many of its products are manufactured on a large scale to stringent specifications, resulting in higher quality with proven lot-to-lot consistency.

Advancement of scientific research is at the core of NEB’s corporate philosophy. NEB researchers have published over 875 peer-reviewed articles to date, in areas including next-generation sequencing, epigenetics, glycobiology, RNA analysis, protein expression, cellular analysis, restriction enzymes, and polymerases. NEB also focuses on subjects outside of its commercial interests—NEB’s Parasitology Research Division is one example of this.

Markets servedNEB serves life science researchers in industry, government, and academia. Across these different market segments, NEB’s reagents are used, both directly and via supply to third-party collaborators, in a variety of applications, including DNA cloning, PCR, epigenetics, RNA analysis, protein expression, purification and analysis, sample preparation for next-generation sequencing, and cellular analysis.

NEB’s reagents are available worldwide through its network of exclusive distributors, agents, and subsidiaries, the latter being located in Canada, China, France, Germany, Japan, Singapore, and the UK.

NEB solutionsThrough its NEBsolutions team, NEB has extended its expertise in enzymology and reagent manufacturing into new and emerging markets, such as molecular diagnostics. Scientific expertise, rapid response times, custom product formulations, and private labeling are just a few of the ways this team assists its customers in reducing their time to market.

NEB’s experienced team of research and production scientists directly assist in the development of its customers’ reagents for their specific application or instrument platform. The NEBsolutions team will work

to optimise reagent formulation, function, and manufacturing process. This often results in reduction of manufacturing costs and the amount of enzyme required, thus lowering the customers’ overall costs.

Using its extensive experience in both business and science, the NEBsolutions team excels at meeting aggressive timelines and offers a rapid lead-time for most custom requests. This includes leveraging the capabilities of the entire company to help customers achieve their goals during all stages of a product’s lifecycle.

NEB solutions is your solutionWith over 20 years of experience in the development and supply of reagents for OEM customers, when you select NEB as your partner, you achieve more than simply sourcing high-quality reagents and production capabilities: you become a part of the team, and NEB, in turn, becomes a part of yours. Bring NEB your product request or your problem, and experience the expertise, responsiveness, flexibility, and quality that NEBsolutions can provide.

Contact Information:New England BiolabsTel: +1 978 927 5054Email: [email protected]: www.neb.com/neb-solutions

Learn which partnering opportunities NEB is actively seeking, and how partnership can bolster your pipeline: view the video at neb.com.

Partner with the NEBsolutions team, and together redefine the traditional OEM relationship: view the video at neb.com

Source R&D14

Company Profiles

Pathology Diagnostics Ltd is an independent GCLP-accredited histopathology research organisation delivering high-quality tissue laboratory & diagnostics services to industry Research & Development scientists

engaged in drug and biomarker development.Specialising in the provision of clinical diagnostics and quantitative

image analysis on human tissues for studies ranging from early discovery to clinical trials, Pathology Diagnostics offers a range of services from traditional histopathology techniques to advanced digital pathology, whole slide scanning, central biorepository services and quantitative image analysis of biomarkers.

Pathology Diagnostics comprises of a team of expert board-certified pathologists and trained scientists / technical

staff with specific experience of particular project needs, including target discovery, preclinical models, clinical trials and tissue-based biomarker testing.

The company can provide a range of services, including: expert tissue diagnostic analysis of human clinical tissue samples by medical pathologists; high-resolution image capture and morphometric image analyses including quantitative image analysis of pharmacodynamic biomarker IHC assays, project management advice by key consultants, tissue laboratory processing and immunohistochemistry.

Its core strengths are its breadth of experience - from molecular biology to human diagnostic pathology, and its ability to interact with scientists and clinicians to support the development of scientific discoveries into new therapeutics and biomarkers for the clinic.

Contact Information:Pathology Diagnostics LtdTel: +44 (0)1223 851354Email: [email protected] Web: www.pathologydiagnostics.com

ProSynth Limited is engaged in all aspects of organic synthesis. For over 22 years the company has provided a wide range of clients with high-quality intermediates, and bespoke services in process development and custom synthesis. It responds

confidentially and accurately to various individual requirements, providing pragmatic solutions in a timely and cost-effective manner.

Operating from purpose-built laboratories close to Cambridge, ProSynth is small enough to care about, and large enough to cope with, projects from 10 grams to 100 kilos and beyond. It holds in excess of one hundred confidentiality agreements and has more than 18,000 procedures documented on its internal database.

The materials produced are examined by a broad range of analytical techniques, including HPLC (chiral where necessary), GC, MS, IR, UV and magnetic resonance spectra. Despatches, whether local or global, are made by qualified shippers and always carry a Certificate of Analysis and Material Safety Data Sheet.

ProSynth’s project management has been highly commended by clients, and routinely includes written weekly updates and a

comprehensive campaign report on completion.ProSynth is the synthesis partner to help advance your ideas from a

sketch in a notebook, through small-scale trials to proof of concept and beyond. The company would be delighted to discuss your requirements.

Contact Information: Prosynth LimitedTel: +44 (0)1787 883320Email: [email protected]: www.prosynth.com

Source R&D 15

Company Profiles

42 Technology LtdTel: +44 (0)1480 302700

Email: [email protected]

Web: www.42technology.com

A4Pbio Tel: +44(0) 1304 249106


Web: www.a4pbio.com

Abcam plcTel: +44 (0)1223 696000


Web: www.abcam.com

Abcodia LtdTel: 07747 765069


Web: www.abcodia.com

Abeterno LtdTel: +44 (0)1223 804055

ABS Laboratories Ltd

Tel: +44 (0)1707 358666


Web: www.abslabs.com

Abzena plcTel: +44 (0)1223 903498


Web: www.abzena.com

Amies Innovation LtdTel: +44 (0)1246 568046


Web: www.amiesinnovation.co.uk

Amphora Research SystemsTel: 0845 2300160


Web: www.amphora-research.com

AMS Biotechnology (Europe) LimitedTel: +44 (0)1235 828200


Web: www.amsbio.co.uk

AnaBioTecTel: + 32 92415640


Web: www.anabiotec.com

APLTel: +46 10 447 96 00


Web: www.apl.se

Aptiv SolutionsTel: +44 (0)1628 643920

Web: www.aptivsolutions.com

Aptus Clinical Limited Tel: +44 (0)1625 238662


Web: www.aptusclinical.com

Aqix LtdTel: +44 (0)20 7554 5852


Web: www.aqix.com

Arecor LimitedTel: +44 (0)1223 426060


Web: www.arecor.com

Argenta Discovery (Charles River Early Discovery)Tel: +44 (0)1279 645645


Web: www.argentadiscovery.com

Argon Design LtdTel: +44 (0)1223 422 355


Web: www.argondesign.com

Ariana PharmaceuticalsTel: +33 1 44 37 17 00

Web: www.arianapharma.com

Asterand UKTel: +44 (0)1763 211600


Web: www.asterand.com

Banook GroupTel: +07500862078

E: [email protected]

Web: www.banook-ci.com

Beckman Coulter GenomicsTel: +44 (0)1279 873837

Web: www.cogenics.com

Biocair International LtdTel: +44 (0)1223 703306


Web: www.biocair.com

BioFocus (Charles River Early Discovery)Tel: +44 (0)1799 533500


Web: www.biofocus.com

BionowTel: 07714 168020


Web: www.bionow.co.uk

Biopharma Technology LtdTel: +44 (0)1962 841 092


Web: www.biopharma.co.uk

Bio-Rad AbD Serotec LtdTel: +44 (0)1865 852700


Web: www.abdserotec.com

Cambridge Bioscience LimitedTel: +44 (0)1223 316855


Web: www.bioscience.co.uk

Cambridge Cell Networks Ltd (CCNet Ltd)Tel: +44 (0)1223 703 137


Web: www.camcellnet.com

Cambridge Epigenetix LimitedTel: +44 (0)1223 804 260


Web: www.cambridge-epigenetix.com

Cambridge Research BiochemicalsTel: +44 (0)1642 567180


Web: www.crbdiscovery.com

Cantab Biopharmaceuticals LtdTel: +44 (0)1223 423 413


Web: www.cantabbio.com

Carbogen Amcis AGTel: 0041 61 935 5353


Web: www.carbogen-amcis.com

Catalent Pharma SolutionsTel (USA): +1 888 765 8846

Tel (Europe): 00800 88556178


Web: www.catalent.com

Charles River Laboratories Early Discovery (Argenta Discovery/BioFocus)Tel: +44 (0)1279 645645


Web: www.criver.com

CRO, CMO and service provider member companies

Entries highlighted in red are featured in the Company Profiles section (pages 7-14)

Contact Information

Source R&D16

Company Profiles

Cisbio BioassaysTel: +33 (0)4 66 79 67 05


Web: www.htrf.com

ClinicaGeno Ltd.Tel: +447779099957


Web: www.clinicageno.com

Cresset BioMolecular Discovery LtdTel: +44 (0)1223 858890


Web: www.cresset-group.com

Cyclofluidic LtdTel: +44 (0)1707 358673

Web: www.cyclofluidic.co.uk

Cytocell LimitedTel: +44 (0)1223 294048


Web: www.cytocell.com

DefiniGENTel: +44 (0)1223 497113


Web: www.definigen.com

deltaDOT LimitedTel: +44 (0)207 691 2075


Web: www.deltadot.com

Domainex LtdTel: +44 (0)1223 743170


Web: www.domainex.co.uk

Dr Reddy’sTel: +44 (0)1223 728010


Web: www.drreddys.com

Dundee Cell Products LtdTel: +44 (0)1382 220749

Email: customerservices@dundeecell-

products.com

Web: www.dundeecellproducts.com

Eagle Genomics LtdTel: +44 (0)1223 654481


Web: www.eaglegenomics.com

Epistem LtdTel: +44 (0)161 606 7258


Web: www.epistem.co.uk

Essen BioScience LtdTel: +44 (0)1707 358685


Web: http://essenbioscience.com

Eurofins PanlabsTel: +44 (0)1494 868557

Email: PanlabsPharmacology@

eurofins.com

Web: www.eurofinspanlabs.com

Europa Bioproducts LtdTel: +44 (0)1353 721118


Web: www.europa-bioproducts.com

Evotec (UK) LtdTel: +44 (0)1235 861561


Web: www.evotec.com

Fahy Gurteen LaboratoriesTel: +44 (0)1223 20 50 40


Web: www.fglabs.com

Fisher BioServicesTel: +44 (0)1279 713320

Web: www.fisherbioservices.com

Fisher Scientific UKTel: +44 (0)1509 231166

Web: www.fisher.co.uk

FluidX LtdEmail: [email protected]

Web: www.fluidx.co.uk

GE HealthcareTel: 08702 407575

Web: www.gehealthcare.com/uken/

Horizon Discovery Group plcTel: +44 (0)1223 655580

Web: www.horizondiscovery.com

Huntingdon Life SciencesTel: +44 (0)1480 892000


Web: www.huntingdon.com

Illumina Cambridge LtdTel: +44 (0)1799 532300


Web: www.illumina.com

Imanova LtdTel: +44 (0)20 8008 6000


Web: www.imanova.co.uk

Integrated Medicines LtdTel: +44 (0)1954 718122

Web: www.integratedmedicines.co.uk

Intertek MelbournTel: +44 (0)1763 261648


Web: www.melbournscientific.com

Isogenica LtdTel: +44 (0)1799 533680


Web: www.isogenica.com

KWS BioTest LtdTel: +44 (0)117 9287886


Web: www.kwsbiotest.co.uk

LGCTel: +44 (0)1992 470 757


Web: www.lgcgenomics.com

Lonza Biologics PlcTel: +44 (0)1753 777000


Web: www.lonzagroup.com

New England Biolabs (UK) LtdTel: +44 (0)1462 420616


Web: www.neb.uk.com

Novus Biologicals LtdTel: +44 (0)1223 426 001


Web: www.novusbio.com

OctoPlus N.V.Tel:+31 71 524 4044


Web: www.octoplus.nl

Pathology Diagnostics LtdTel: +44 (0)1223 851 354


Web: www.pathologydiagnostics.com

Pharmidex Pharmaceutical Services LtdTel: 0870 240 5978


Web: www.pharmidex.com

PharmorphixTel: +44 (0)1223 425105


Web: www.safcglobal.com

Physiomics plcTel: +44 (0)1865 784980


Web: www.physiomics-plc.com

Population Genetics Technologies LtdTel: +44 (0)1223 497357


Web: www.populationgenetics.com

PRECOS Ltd (a Crown Bioscience Company)Tel: 0870 166 6234


Web: www.crownbio.com

Promega UK LtdTele: 023 8076 0225


Web: www.promega.com

Prosarix LtdTel: +44 (0)1223 870400


Web: www.prosarix.com

Prosynth LtdTel: +44 (0)1787 883320


Web: www.prosynth.com

QCTR LtdTel: +44 (0)1786 270400


Web: www.qctr.co.uk

Contact Information

Source R&D 17

Company Profiles

Agenda 1 Analytical ServicesTel: +44 (0)1274 326073


Web: www.agenda1.co.uk

Alderley Analytical LtdTel: +44 (0)1625 238610

Email: elizabeth Thomas@Alderley

analytical.co.uk

Web: www.alderleyanalytical.co.uk/

Almac GroupTel: 028 3833 2200


Web: www.almacgroup.com

Aptus ClinicalTel: +44 (0)1625 238662


Web: www.aptusclinical.com

Cobra Biomanufacturing plcTel: +44 (0)1782 714181


Web: www.cobrabio.com

Cyprotex plcTel: +44 (0)1625 505 100


Web: www.cyprotex.com

Euprotec Limited

Tel: +44 (0)161 820 3620


Web: www.euprotec.com

Gaea Clinical LtdTel: +44 (0)1625 413900


Web: www.gaea.co.uk

HematogenixTel: +44 (0)1708 4688700


Web: www.hematogenix.com

High Force Research LtdTel: +44 (0)191 3779098


Web: www.highforceresearch.com

Illingworth Research LtdTel: +44 (0)1625 617447


Web: www.illingworthresearch.com

Intertek Clinical Research ServicesTel: +44 (0)161 232 4690


Web: www.intertek.com/4Front

Intertek MSG

Tel: +44 (0)1642 435766


Web: www.intertek.com

Intertek

Pharmaceutical Services

Tel: +44 (0)161 721 5247


Web: www.intertek.com/pharmaceu-

tical/asg

Orla Protein

Technologies Ltd

Tel: +44 (0)191 231 3127


Web: www.orlaproteins.com

Patheon

Tel: +44 (0)1793 524411


Web: www.patheon.com

Peakdale

Molecular Ltd

Tel: +44 (0)1298 816 700


Web: www.peakdale.com

Perfectus Biomedical Ltd

Tel: +44 (0)7841 342904


Web: www.perfectus-medical.com

Protein

Technologies Ltd

Tel: +44 (0)161 226 2366


Web: www.protein-technologies.com

Research Nurses Ltd

Tel: +44 (0)1625 662944


Web: www.researchnurses.co

Tomorrows

Medicines Limited

Tel: +44 (0)1925 607125

Email: dr.cj.nolan@tomorrows

medicines.com

Web: https://yourtreatment

choices.com

Unilabs (York

Bioanalytical Laboratories)

Tel: +44 (0)1904 686060


Web: www.york-bio.com

QuintilesE: [email protected]

Web: www.quintiles.com

Quotient Clinical LtdTel: +44 (0)1159 749000


Web: www.quotientclinical.co.uk

SEEK (formerly PepTcell Limited)Tel: +44 (0)20 7153 6570

Web: www.seekacure.com

Selcia LtdTel: +44 (0)1277 367000

Email: [email protected].

Web: www.selcia.com

Sera Laboratories International LtdTel: +44 (0)1444 250010

Web: www.seralab.co.uk

SGS M-Scan LtdTel: (0)118 989 6940


Web: www.m-scan.com

Sigma-AldrichTel: +44 (0)1440 767000


Web: www.sigma-aldrich.com

Stem Cell Sciences (UK) LtdTel: +44 (0)1223 499160

Web: www.stemcellsinc.com

Sygnature Discovery LtdTel: +44 (0)1159 415401


Web: www.sygnaturediscovery.com

SYNthesis med chemTel: +44 (0)1223 804051


Web: www.synmedchem.com

TwistDx LtdTel: +44 (0)1223 496700


Web: www.twistdx.co.uk

Vetter Pharma International GmbHTel: +49 (0)751 3700 0


Web: www.vetter-pharma.com

CRO, CMO and service provider member companies

Contact Information

Source R&D18

Company ProfilesContact Information

ACM GlobalTel: +44 (0)1904 699400

Web: www.acmgloballab.com

Acumen Pharmaceutical Services LtdTel: +44 (0)161 877 5300

Email: wayne.griffin@acumenpharma.

co.uk

Web: www.acumenpharma.co.uk

AF ChemPharm LimitedTel: +44 (0)114 3277279


Web: www.afchempharm.co.uk

Alpha BiolaboratoriesTel: +44 (0)845 50 50 001


Web: www.alphabiolabs.com

AMRI UKTel: +44 (0)1352 717100


Web: www.amriglobal.com

Applied Cytometry SystemsTel: +44 (0)1909 547210

Email: customersupport@appliedcy-

tometry.com

Web: www.appliedcytometry.com

BioInnovel LtdTel: +44 90)191 516 6542


Web: www.bioinnovel.com

BioServ UK LimitedTel: +44 (0)114 224 2235


Web: www.bioservuk.com

CARBOGEN AMCIS LtdTel: +44 (0)161 2233344


Web: www.carbogen-amcis.com

Centre for Process InnovationTel: +44 (0)1642 442481


Web: www.uk-cpi.com

Cica Biomedical LtdTel: +44 (0)1423 799091


Web: www.cica-biomedical.com

Drew Scientific Co LimitedTel: +44 (0)1229 432089


Web: www.drew-scientific.com

Edwards AnalyticalTel: +44 (0)1325 327315


Web: www.edwards-analytical.com

ePitope Informatics LtdTel: +44 (0)1434 609962

Email: glenn.major@epitope-informat-

ics.com

Web: www.epitope-informatics.com

EurogentecTel: +44 (0)1794 511411


Web: www.eurogentec.com

Fujifilm Diosynth BiotechnologiesTel: +44 (0)1642 363511


Web: www.fujifilmdiosynth.com

Geneius Laboratories LtdTel: +44 (0)191 243 0871


Web: www.geneiuslabs.co.uk

Hall Analytical Laboratories LtdTel: +44 (0)161 286 7889


Web: www.hallanalytical.co.uk

ICON Development SolutionsTel: +44 (0)1628 496326


Web: www.iconplc.com

Insight Chemical Solutions LtdTel: +44 (0)151 795 4193

Web: www.insightchemicalsolutions.

co.uk

Intelligent Pharma LimitedTel: +44 (0)191 478 8120

Web: www.intelligentpharma.co.uk

Keane Analytical LtdTel: +44 (0)1434 672542Web: www.keane-analytical.co.uk

Lab M LtdTel: +44 (0)161 797 5729Email: [email protected]: www.labm.com

LPD Laboratory Services LtdTel: +44 (0)1254 676074Email: [email protected]: www.lpdlabservices.co.uk

M & A PharmachemTel: +44 (0)1942 816184Web: www.mapharmachem.co.uk

Medicines Evaluation UnitTel: +44 (0)161 946 4050Email: [email protected]: www.meu.org.uk

National Genetics Reference LaboratoryTel: +44 (0)161 276 8703Web: www.ngrl.org.uk

NewChem TechnologiesTel: +44 (0)191 375 7294E: [email protected]: www.newchemtechnologies.com

Newtec Laboratories (Eurofins)Tel: +44 (0)1642 370321Email: [email protected]: www.eurofins.co.uk

Onyx Scientific LtdTel: +44 (0)191 516 6516Email: [email protected]: www.onyx-scientific.com

ParexelTel: +44 (0)114 225 1000Email: [email protected]: www.parexel.com

Pharmapac UK LtdTel: +44 (0)151 670 9090Email: [email protected]

Web: www.pharmapacuk.com

Phasefocus LtdTel: +44 (0)114 2866377


Web: www.phasefocus.com

Quay PharmaceuticalsTel: +44 (0)1244 837000


Web: www.quaypharma.com

RecipharmTel: +44 (0)161 342 6271


Web: www.recipharm.com

Simcyp LtdTel: +44 (0)114 2922322

Web: www.simcyp.com

Smerud Medical Research UK LtdTel: +44 (0)161 870 8127

Web: www.smerud.com

The Clinical Trial Company Ltd (TCTC)01565 733 772


Web: www.theclinicaltrialcompany.com

UK BiobankTel: +44 (0)161 475 5360


Web: www.ukbiobank.ac.uk

UK BiocentreTel: +44 (0)161 475 5377


Web: www.ukbiocentre.com

Universal Products LtdTel: +44 (0)1772 685777

Web: www.universal-laboratories.co.uk

Vickers Laboratories LtdTel: +44 (0)113 236 2811


Web: www.viclabs.co.uk

Yorkshire Bioscience LtdTel: +44 (0)1904 561592


Web: www.york-bio.com

Additional CRO, CMO and service provider companies

Source R&D 19

Company Profiles

Bionow is an award-winning specialist business development and services company serving the biomedical sector across the North of England. Our mission is to provide the tools and support for

industry, through our range of specialist products and services

Features of Bionow membership include access to industry-renowned awards and conferences, mentoring and training, a

discounted rates on general business products and services, dedicated business support programmes, online networking and access to a vibrant network of businesses

To speak to us about membership and the savings that can be achieved, please contact Dr Diane Cresswell on 07766 991 932 or

email us: [email protected] www.bionow.co.uk

Source R&D20

Company Profiles

leading analytical expertise. more products.Whether you require analytical, physical, biological or microbiological techniques, we help you create a faster path to regulatory approval and market.

Call: + 1 888 SOLUTION (765 8846)

Europe: 00800 88 55 6178Email: [email protected] Visit: www.catalent.com

© 2

012

Cat

alen

t Pha

rma

Solu

tion

s. A

ll ri

ghts

rese

rved

.

analytical services

BROAD CAPABILITIES, TAILORED SOLUTIONSFrom characterization to method development to viral clearance and lot testing, we can tailor an analytical program to fit your needs and timelines.

LOCAL EXPERTISE, GLOBAL REACH Our facilities in the US, UK and Germany provide local expertise and worldwide coverage.

LARGE & SMALL MOLECULE SERVICESFrom rapid testing of early candidates to regulatory submission, we can support your toughest molecules.

WORLD’S LARGEST STABILITY CAPACITY & PROVEN EXPERTISEWe have 70,000+ cu.ft. of capacity across the US and EU supported by 300+ degreed scientists and professionals, including 50+ PhD’s.

Every molecule has a challenge. We have a solution.

DEVELOPMENT DELIVERY SUPPLY

source r&d directory

Documents